Medical Data Vision Co.Ltd. (3902) AI Stock Analysis

• Market Cap: ¥17.67B
• Dividend Yield: 1.19%
• Average Volume (3M): 221.94K
• Price to Earnings (P/E): 4465.7
• Beta (1Y): 0.99
• Revenue Growth: -0.58%
• EPS Growth: -260.22%
• Country: JP
• Employees: 315
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.60
• Shares Outstanding: 40,027,527
• 10 Day Avg. Volume: 317,960
• 30 Day Avg. Volume: 221,940
• PEG Ratio: 0.10
• Price to Book (P/B): 4.84
• Price to Sales (P/S): 2.54
• P/FCF Ratio: -14.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: ―

Medical Data Vision Co. Ltd. faces significant challenges, primarily due to declining financial performance with negative profitability and cash flow issues. The bearish technical indicators further exacerbate the situation, while a negative P/E ratio indicates poor valuation. The company must address these financial and operational inefficiencies to improve its stock performance.

Medical Data Vision Co.Ltd. Business Overview & Revenue Model

Company Description

Medical Data Vision Co., Ltd. (3902) is a Japanese company that specializes in providing healthcare IT solutions with a focus on big data analytics and electronic medical records. The company operates in the healthcare technology sector, offering services and products that support hospitals, clinics, and other healthcare organizations in improving their operations through data-driven insights. Its core products include software platforms and systems for medical data management and analysis.

How the Company Makes Money

Medical Data Vision Co., Ltd. makes money primarily through the sale and subscription of its healthcare IT solutions. The company's key revenue streams include licensing fees for its software products, subscription fees for its cloud-based services, and consulting fees for implementation and support services. Additionally, the company may generate income from partnerships with other healthcare technology firms and institutions, as well as from providing data analytics services to healthcare providers looking to optimize their operations and improve patient outcomes.

Medical Data Vision Co.Ltd. Financial Statement Overview

Summary

Medical Data Vision Co. Ltd. faces financial headwinds, with declining revenues and profitability impacting its income statement. While the balance sheet shows resilience due to no leverage, the negative cash flow trends highlight potential liquidity concerns. The company should focus on improving operational efficiency and cash flow management to enhance its financial health.

Income Statement

The company experienced a significant decline in revenue and profitability. The gross profit margin decreased from previous years, and the net profit margin turned negative in 2024, indicating profitability challenges. The EBIT and EBITDA margins also showed substantial deterioration, reflecting operational inefficiencies and financial strain.

Balance Sheet

The balance sheet remains strong with no debt, suggesting financial stability. The equity ratio is solid, indicating a high proportion of assets are funded by equity. However, the decline in stockholders' equity and total assets in 2024 suggests a reduction in financial resources.

Cash Flow

Cash flow metrics reveal significant issues, particularly with negative operating cash flow and free cash flow in 2024. The free cash flow to net income ratio has deteriorated, indicating cash flow constraints. This poses risks to the company's financial flexibility and ability to fund operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.16B	5.91B	6.42B	6.10B	5.67B	4.58B
Gross Profit	4.40B	4.33B	5.03B	5.03B	4.64B	3.88B
EBITDA	88.91M	130.00M	1.87B	1.91B	1.73B	1.31B
Net Income	-715.18M	-791.17M	979.13M	870.51M	1.09B	700.22M
Balance Sheet
Total Assets	4.63B	4.75B	6.23B	4.90B	5.53B	5.32B
Cash, Cash Equivalents and Short-Term Investments	1.83B	1.35B	3.22B	2.26B	3.22B	3.19B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.80B	1.59B	1.91B	1.29B	1.33B	1.18B
Stockholders Equity	2.80B	3.10B	4.25B	3.52B	4.16B	4.10B
Cash Flow
Free Cash Flow	0.00	-1.03B	1.59B	857.55M	1.06B	937.32M
Operating Cash Flow	0.00	-877.85M	1.62B	910.79M	1.08B	964.37M
Investing Cash Flow	0.00	-592.97M	-437.83M	-868.75M	-26.93M	-142.58M
Financing Cash Flow	0.00	-399.00M	-225.26M	-979.36M	-1.03B	-589.64M

Medical Data Vision Co.Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 453.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3902, the sentiment is Negative. The current price of 453 is below the 20-day moving average (MA) of 563.15, below the 50-day MA of 561.94, and below the 200-day MA of 460.80, indicating a bearish trend. The MACD of -24.05 indicates Positive momentum. The RSI at 26.76 is Positive, neither overbought nor oversold. The STOCH value of 3.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3902.

Medical Data Vision Co.Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3649	79 Outperform	¥20.67B	18.03	―	2.00%	-6.29%	-22.25%
4320	73 Outperform	¥15.01B	14.26	―	2.48%	7.79%	38592.95%
6095	72 Outperform	¥15.32B	10.15	―	0.65%	-17.86%	133.08%
3939	65 Neutral	¥22.00B	21.63	―	1.62%	13.39%	12.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
3902	43 Neutral	¥17.67B	4,465.71	―	1.19%	-0.58%	-260.22%

Medical Data Vision Co.Ltd. Corporate Events

Medical Data Vision’s Plan to Meet Tokyo Stock Exchange Criteria

Medical Data Vision Co., Ltd. has announced that it currently does not meet the Tokyo Stock Exchange Prime Market’s criteria for ‘Tradable Shares Market Capitalization’ as of December 31, 2024. The company has devised a compliance plan to meet these criteria by December 31, 2026, and is actively working to enhance its corporate value while engaging with shareholders and stakeholders.

Medical Data Vision Co. Reports Financial Decline but Projects Recovery

Medical Data Vision Co., Ltd. reported a significant decline in its financial performance for the fiscal year ended December 31, 2024, with a notable drop in net sales and a substantial net loss compared to the previous year. Despite these setbacks, the company forecasts a strong recovery for 2025, anticipating significant growth in net sales and a return to profitability, which suggests an optimistic outlook for future operations.